Therapeutic effect of Jinlongshe Granule (金龙蛇颗粒) on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: A double-blind placebo-controlled clinical trial

Chinese Journal of Integrative Medicine

Volumn 21, Issue 8, 2015, Pages 579-586

  Sun, Da Zhi ^a   Jiao, Jian Peng ^a   Zhang, Xuan ^a   Xu, Jing Yu ^a   Ye, Min ^a   Xiu, Li Juan ^a   Zhao, Ying ^a   Lu, Ye ^a   Liu, Xuan ^a   Zhao, Jing ^a   Shi, Jun ^a   Qin, Zhi Feng ^a   Wei, Pin Kang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

gastric cancer; Jinlongshe Granule; quality of life; randomized placebo controlled study

Indexed keywords

ANTINEOPLASTIC AGENT; HERBACEOUS AGENT; JINLONGSHE GRANULE; PLACEBO; UNCLASSIFIED DRUG; JINLONGSHE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CHINESE MEDICINE; CLINICAL ARTICLE; COGNITION; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; EMOTION; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER CORE QUALITY OF LIFE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; LOSS OF APPETITE; MALE; MIDDLE AGED; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; STOMACH CANCER; TREATMENT DURATION; ADOLESCENT; PATHOPHYSIOLOGY; STOMACH NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; HUMANS; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 84938420802     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-014-1950-z     Document Type: Article

References (39)

1. Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of taxanes. Oncologist 2004;9(suppl 2):9–15.
2. Velikova G, Weis J, Hjermstad MJ, Kopp M, Morris P, Watson M, et al. The EORTC QLQ-HDC29: a supplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. Eur J Cancer 2007;43:87–94.
3. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135–1139.
4. Kato J, Nagahara A, Iijima K, Yoshimura M, Osada T, Yoshizawa T, et al. Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan. J Gastroenterol Hepatol 2008;23(Suppl 2):S268–S272.
5. Que HF, Chen HF, Xu JN, Liu S, Lu DM, Tang HJ. Discussion of relationship between quality of life and clinical effect assessment of malignant tumor treated with traditional Chinese medicine. J Chin Integr Med (Chin) 2005;3:253–256.
6. Wei PK, Xu L, Sun DZ, Shi J, Qin ZF, Lu Y. Relation between phlegm and generation and development of Gastric Cancer. J Tradit Chin Med 2008;28:152–155.
7. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 2001;37:966–971.
8. Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer 2011;14:301–316.
9. Sun DZ, Xu L, Wei PK, Liu L, He J. Syndrome differentiation in traditional Chinese medicine and E-cadherin/ICAM-1 gene protein expression in gastric carcinoma. World J Gastroenterol 2007;13:4321–4327.
10. Roca O, Pérez-Terán P, Masclans JR, Pérez L, Galve E, Evangelista A, et al. Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy: high flow nasal cannula in heart failure. J Crit Care 2013;28:741–746.
11. Combe C1, McCullough KP, Asano Y, Ginsberg N, Maroni BJ, Pifer TB. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices. Am J Kidney Dis 2004;44(5 Suppl 2):39–46.
12. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
13. Zheng XY, ed. Chinese medicine clinical research guidelines. Beijing: Chinese Medical Science and Technology Press; 2002:29–32.
14. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043-3045.
15. Food and Drug Administration. Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. US Food-Washington, DC, US Food and Drug Administration, 2007.
16. Sun DZ, Ju DW, He J, Lu Y, Wu F, Li C, et al. Tumor interstitial fluid and postoperative recurrence of tumors: an experimental study for verifying hypothesis of "tumor-phlegm microenvironment". J Tradit Chin Med 2010;16:435–441.
17. Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair 2010;3:12.
18. Wang JY, Xu L, Zhang RX, Lao L. Traditional Chinese medicine for cancer pain. J Chin Integr Med (Chin) 2011;9:129–134.
19. You J. Significance and necessity of developing quality of life questionnaire for cancer patients adapting to traditional Chinese medicine. J Chin Integr Med (Chin) 2006;4:473–477.
20. Lin LZ, Zhou DH, Zheng XT. Effect of traditional Chinese medicine in improving quality of life of patients with non-small cell lung cancer in late stage. Chin J Integr Tradit West Med (Chin) 2006;26:389–393.
21. Liu X, Hua BJ. Effect of traditional Chinese medicine on quality of life and survival period in patients with progressive gastric cancer. Chin J Integr Tradit West Med (Chin) 2008;28:105–107.
22. Zhou W, Li YJ, Wei PK. Effects of Xiaotan Sanjie Recipe on vasculogenic mimicry of human gastric cancer xenografts in nude mice. Chin J Integr Tradit West Med (Chin) 2011;31:532–536.
23. Pang B, Wei PK, Li YJ. Effect of xiaotan sanjie recipe on expressions of VEGF-C and VEGFR-3 in nude mice with transplanted human gastric adenocarcinoma cell MKN-45. Chin J Integr Tradit West Med (Chin) 2011;31:204–208.
24. Li CJ, Wei PK, Yue BL. Study on the mechanism of Xiaotan Sanjie Recipe for inhibiting proliferation of gastric cancer cells. J Tradit Chin Med(Chin) 2010;30:249–253.
25. Ju DW, Wei PK, Lin HM, Sun DZ, Yu S, Xiu LJ. Effects of Xiaotan Sanjie Decoction on expressions of interleukin-8 and its receptors in gastric tumor xenografts and gastric tissue adjacent to the tumor in mice. J Chin Integr Med (Chin) 2010;8:74–79.
26. Guo XD, Wei PK. Effect of Xiaotan Sanjie Recipe on growth of transplanted tumor and expressions of proliferating cell nuclear antigen and epidermal growth factor receptor in tissue of gastric carcinoma of nude mice. J Chin Integr Med (Chin) 2007;5:432–436.
27. Zheng J, Zheng J, Zheng PY. Application of quality of life scale in evaluating the efficacy of gastric cancer treatment. J Chin Integr Med (Chin) 2008;6:304–310.
28. Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Jpn J Clin Oncol 2011;41:519–529.
29. Arraras Urdaniz JI, Villafranca Iturre E, Arias de la Vega F, Domínguez Domínguez MA, Lainez Milagro N, Manterola Burgaleta A, et al. The eortc quality of life questionnaire QLQ-C30 (version 3.0). Validation study for Spanish prostate cancer patients. Arch Esp Urol 2008;61:949–954.
30. Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Sirachainan E, Ratanatharathorn V. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version. Qual Life Res 2006;15:167–172.
31. Luo N, Fones CS, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore. Qual Life Res 2005;14:1181–1186.
32. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997;50:441–450.
33. Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, et al. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res 2008;17:207–214.
34. Rodary C, Pezet-Langevin V, Garcia-Acosta S, Lesimple T, Lortholary A, Kaminsky MC, et al. Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer 2004;40:521–528.
35. Wan C, Meng Q, Yang Z, Tu X, Feng C, Tang X, et al. Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Ann Oncol 2008;19:2053–2060.
36. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 2000;9:129–137.
37. Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006;6:274.
38. Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH, et al. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol 2006;57:289–294.
39. Cao ND, Zhao AG, Yang JK. Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy. J Chin Integr Med (Chin) 2010;8:116–120.